Cancer News and Research

Latest Cancer News and Research

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

Phase Forward’s InForm GTM electronic data capture solution to be implemented by Bausch & Lomb

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year contract with renowned eye health company Bausch & Lomb. The agreement calls for Bausch & Lomb to implement Phase Forward’s InForm™ Global Trial Management (GTM) electronic data capture (EDC) solution, including the Central Coding™ module, in all of its trials, including Surgical, Vision Care and Pharmaceuticals products.

29 Oct 2009

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

New technology enhancements from Varian Medical Systems, designed to make radiotherapy and radiosurgery treatments faster, more accurate, and easier to plan and deliver, will be on display at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Chicago next week.

29 Oct 2009

World’s first Cesium-131 lung implants performed

IsoRay, Inc. announced today that starting on August 12, 2009, Dr. Bhupesh Parashar from the Department of Radiation Oncology, and Dr. Nasser Altorki of the Department of Cardiothoracic Surgery at Weill Cornell Medical Center performed the world’s first Cesium-131 lung implants.

29 Oct 2009

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

29 Oct 2009

Novian Health and Rose Medical Center sign an agreement to provide Novilase laser treatment to treat breast lumps

Novian Health, manufacturer of Novilase™ Breast Therapy for benign breast tumors, announced an agreement with Rose Medical Center for Rose to provide the Novilase laser treatment to treat breast lumps.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Endo Pharmaceuticals today reported financial results for the third quarter of 2009.

29 Oct 2009

WaveMark CIMS implemented at St. Joseph’s Hospital

WaveMark, Inc., a leading provider of real-time inventory management (RTIM) solutions for high value medical products, and St. Joseph’s Hospital of Atlanta, GA today announced the use of WaveMark’s hospital inventory management solution, WaveMark CIMS™, by St. Joseph’s Hospital to manage its high value, specialty inventory. St. Joseph’s will use WaveMark’s point of use RTIM technology to track physician preference items in its Cardiac Cath and Electrophysiology (EP) labs.

29 Oct 2009

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.

29 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

Neogenomics declares third quarter 2009 financial results; significantly improved liquidity position

NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2009.

29 Oct 2009

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.

29 Oct 2009

Third quarter 2009 financial results announced by United Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2009.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Curis

Curis, Inc., a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the third quarter ended September 30, 2009.

29 Oct 2009

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Foreign body ingestion is a frequent gastrointestinal emergency. However, long spoon swallowing is a rare event. Most swallowed spoons have been found in the stomach. Previously, there has been no reported case of a long spoon reaching the jejunum.

29 Oct 2009

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Blood glucose levels in a lot of patients fed normal liquid food (NLF) and a high calorie diet (HCD) were high. There was no significant difference in the blood prealbumin levels. There was a significant increase in the blood cortisol levels in some patients. The stress of surgery may be tolerated by children by feeding up to 2 h before elective surgery.

29 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Phase Forward’s InForm GTM electronic data capture solution to be implemented by Bausch & Lomb

Varian Medical Systems to showcase future technologies for managing cancer at the ASTRO

World’s first Cesium-131 lung implants performed

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Novian Health and Rose Medical Center sign an agreement to provide Novilase laser treatment to treat breast lumps

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

WaveMark CIMS implemented at St. Joseph’s Hospital

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

Positive results from Genta's Phase 3 trial of Genasense

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Third-quarter 2009 financial results of Antigenics announced

Neogenomics declares third quarter 2009 financial results; significantly improved liquidity position

BioCryst Pharmaceuticals reports fiscal 2009 third-quarter results

Third quarter 2009 financial results announced by United Therapeutics

Third-quarter fiscal 2009 results announced by Curis

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

World Journal of Gastroenterology reports a case of metallic foreign body in lower mid-abdomen

Perioperative oral dietary supplements before elective surgery offers no functional benefit

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in